Skip to main content

Biologic/Novel Rx

Thromboembolic Risk with Tofacitinib in RA, PsA and UC

Aug 06, 2020

An analysis of the tofacitinib (Xeljanz) drug development program in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis suggests a low level risk for venous (VTE) and arterial thromboembolism (ATE).  



In the last 2 years, observational data has

Read Article

Long-Term Rituximab in ANCA-Associated Vasculitis

Aug 06, 2020

The Annals of Internal Medicine reports that biannual rituximab infusions over 18 months was effective at maintaining remission in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).

Read Article

IL-1 Blockade: A Treatment at Last for Osteoarthritis?

Aug 05, 2020

The interleukin (IL)-1β inhibitor canakinumab (Ilaris) showed promise for preventing the need for hip or knee replacement among patients with osteoarthritis in an exploratory analysis of data from a randomized clinical trial, investigators reported.

Among patients enrolled in CANTOS, the pooled

Read Article

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jul 31, 2020

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article

Methotrexate Improves Pegloticase Efficacy and Tolerability

Jul 29, 2020

The efficacy of intravenous pegloticase (PEG) therapy in gout can be limited by its toxicity, but when coadministered with weekly methotrexate, higher response rates and less toxicity was observed.



In published gout clinical trials, the PEG responder rate was 42%. Strategies to limit 

Read Article

The Burden of Gout

Jul 28, 2020

Danve and Neogi have an editorial in the current Arthritis & Rheumatology about the burden of gout that affects 41 million adults worldwide, according to the Global Burden of Disease Study 2017 (GBD 2017) also published in the same issue.

This makes gout twice as prevalent as rheumatoid

Read Article

GI Perforations with Tocilizumab Greater than Other Biologics

Jul 27, 2020

A study from a Swedish population shows the real-world risk of gastrointestinal (GI) perforations in rheumatoid arthritis (RA) patients taking biologics finds that the risk was greatest in RA patients taking tocilizumab (TCZ), compared with RA patient taking tumour necrosis factor inhibitors (

Read Article

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jul 24, 2020

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Read Article

Low Risk of COVID in Biologic Treated Rheum Patients

Jul 23, 2020

In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population. 



Their study included 295

Read Article

For TNF Response in RA, Weight Matters

Jul 22, 2020

Patients with rheumatoid arthritis (RA) who were obese were significantly less likely to remain on treatment with tumor necrosis factor (TNF) inhibitors -- but so were those who were underweight, a large, long-term study determined.

Compared with patients with normal weight, patients in obesity

Read Article

Steroids and Tocilizumab in Cytokine Storm Syndrome

Jul 21, 2020

A recent study from the Netherlands has shown that patients with severe COVID-19-associated cytokine storm syndrome (CSS)  with high dose steroids and tocilizumab had a faster recovery, less need for invasive mechanical ventilation and fewer deaths when compared to CSS patients receiving

Read Article

Risankizumab Outduels Secukinumab in Psoriasis

Jul 20, 2020

The IMMerge trial has demonstrated the superiority of interleukin (IL)‐23 over IL-17A inhibition adults with plaque psoriasis.



This multicenter, phase 3, open‐label study enrolled 327 adult patients with chronic, moderate‐to‐severe plaque psoriasis who were randomised risankizumab (

Read Article
RheumNow Podcast is Up! Listen to Fauci! Watch it here>> https://t.co/dHq3fP85Ip or Listen to the Podcast>> https://t.co/LdHO7fKUCp

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2020

RheumNow Podcast – LTF – Listen to Fauci (7.17.20)

Jul 17, 2020

Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow. Let's dig into this week's 14 highlights.

Read Article

Anti-Rheumatic Therapies for COVID-19 Infection

Jul 15, 2020

Since the onset of the COVID-19 pandemic numerous anti-rheumatic therapies have been proposed as being potentially beneficial. The mechanistic effects of these agents, either presumed antiviral, anti-inflammatory and anti-thrombotic effects, may benefit mitigate the damage seen with COVID-19

Read Article
Canadian 1484 incident early #RA pts (enrolled 2007–2017). SC MTX monotherapy had fewer Rx changes(45% SC vs 79% PO)with longer treatment duration. Similarly taking biologics or triple therapy had a longer time without treatment change. https://t.co/babj1MvTNB

Dr. John Cush RheumNow ( View Tweet)

Jul 15, 2020

JAK Inhibitor Succeeds as Monotherapy in Rheumatoid Arthritis

Jul 14, 2020

The oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) given as monotherapy was more effective than methotrexate alone in methotrexate-naive patients with active rheumatoid arthritis (RA) in a multinational phase III trial.

Read Article

IL-17 Superior to TNF Inhibition in Psoriatic Arthritis

Jul 14, 2020

A one year head-to-head (H2H) trial has shown ixekizumab (IXE) to be superior to adalimumab (ADA) in psoriatic arthritis (PsA); for both skin and articular outcomes.

The SPIRIT H2H study was a 52-week trial of 566 biologic DMARD naive, PsA patients, randomized to received either IXE or ADA. The

Read Article
FDA has approved a 6th adalimumab biosimilar - called Hulio (adalimumab-fkjp) with indications of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, psoriasis.

Dr. John Cush RheumNow ( View Tweet)

Jul 13, 2020

ICYMI: Protective Benefit of Colchicine in COVID-19 Infection

Jul 10, 2020

Colchicine has been advocated as a potential anti-inflammatory intervention in patients with the coronavirus 2 infection and clinical trials have been developed to assess its effect in early COVID-2 infection.  JAMA has published a randomized clinical trial showing that low dose colchicine had

Read Article

ICYMI: COVID-19 and Thrombotic Complications

Jul 08, 2020

Severe and fatal outcomes with coronavirus infection are often the result of the downstream damage that follows the viral infection. Rising high on the list of complications are the hematologic and vascular complications seen in severely affected patients, so much so that many centers are

Read Article
Rheumatology Round-Up from #EULAR2020 w/ Drs. Kavanaugh & Cush.

Dr. John Cush RheumNow ( View Tweet)

Jul 07, 2020
Rheumatoid Arthritis: Pathogenesis, Prediction and Prevention – An Emerging Paradigm Shift https://t.co/uNDsLmgaN7 #RA #prevention #Rituximab - nice article, still think if repeated Ritux to eliminate pathogenic abs would significantly prevent RA

Peter Nash drpnash ( View Tweet)

Jul 06, 2020

RheumNow Podcast – Gout Guidelines (7.3.20)

Jul 03, 2020

Dr Jack Cush reviews the journal reports and news from RheumNow this past week. Highlights include:

Read Article

2020 ACR Gout Management Guideline

Jul 03, 2020

In May, the American College of Rheumatology (ACR) released the"2020 Guideline for the Management of Gout"reflecting new clinical evidence since the last guideline published in 2012.



The guideline puts forth 42 recommendations, including 16 strong recommendations, based in 52 PICO

Read Article
×